Results 221 to 230 of about 17,663 (255)
Some of the next articles are maybe not open access.
Non–Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation
Annual Review of Medicine, 2019Atrial fibrillation (AF) increases a patient's stroke risk four- to five-fold. Anticoagulation with the vitamin K antagonist (VKA) warfarin reduces the risk of stroke by 67%, but warfarin carries a significant risk of major bleeding and has unpredictable pharmacodynamics with a narrow therapeutic window, necessitating frequent monitoring of its ...
Alexander C, Fanaroff, E Magnus, Ohman
openaire +2 more sources
Converting patients from warfarin to non-vitamin K antagonist oral anticoagulants
Journal of the American Association of Nurse Practitioners, 2023ABSTRACT Background: Non-vitamin K antagonist oral anticoagulants (NOACs) are favorable in stroke prevention for geriatric patients with nonvalvular atrial fibrillation versus warfarin. These anticoagulants do not require international normalized ratio (INR) monitoring and have lower food/drug interactions.
Sarah Romanelli, Veronica Rivera
openaire +2 more sources
Non–vitamin K antagonist oral anticoagulant reversal: hope is on the horizon
The American Journal of Surgery, 2016Non-vitamin K oral anticoagulants have become an attractive alternative to warfarin when patients require anticoagulation. Until recently, one of the biggest challenges to these agents was the lack of specific reversal of their anticoagulation when bleeding occurs or urgent/emergent procedures are required.This article is a narrative review of peer ...
openaire +2 more sources
Safe administration of non-vitamin K antagonist oral anticoagulants
Nurse Prescribing, 2017Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. More than 1 million people in the UK have AF, and it is more prevalent in older people. It increases the risk of stroke fivefold ( Stroke Association, 2016a ). In 2009, non-vitamin K antagonist anticoagulants (NOACs) were integrated into clinical practice for the treatment of ...
openaire +1 more source
Non-Vitamin K Antagonist Oral Anticoagulants
Chest, 2014Gregory Y.H Lip +4 more
openaire +1 more source
Non-vitamin K antagonist oral anticoagulants and the management of bleeding
Medicine, 2017In recent years, non-vitamin K antagonist oral anticoagulants (NOACs) have become an increasingly popular choice in the treatment and prevention of venous and arterial thromboembolism, owing to the convenience of fixed dosing. Large Phase III studies and meta-analyses have shown that the risk of intracranial and fatal bleeding with NOACs is lower than ...
openaire +1 more source
[Reversal strategies for non-vitamin K antagonist oral anticoagulants].
Ugeskrift for laeger, 2018Non-vitamin K oral anticoagulants (NOACs) are alternatives to vitamin K antagonists and provide consistent anticoagulation with equal or better clinical outcome and no need for routine monitoring. Bleeding is a feared complication of anticoagulants. Until recently, no specific agent has been available for reversal of NOACs.
Frederik Uttenthal, Larsen +2 more
openaire +1 more source
Non-vitamin K antagonist oral anticoagulants in valvular atrial fibrillation
International Journal of Cardiology, 2016Özcan Başaran +3 more
openaire +2 more sources